u/Electrical_County_61 — reddlx

People are drinking less. Here’s why Heineken is doing just fine.

Global alcohol consumption is undeniably facing headwinds right now, with shifting demographics and health trends putting real pressure on traditional beer volumes.

I just published a financial and strategic deep dive on Heineken, specifically looking at how they are navigating this challenging macro environment. While the broader market is sobering up, my research suggests that Heineken has built a surprisingly resilient framework to handle the downturn.

Here are a few key takeaways from the analysis on why they are holding their ground:

• Premiumization over Volume: Instead of fighting a losing battle for pure volume growth, Heineken is successfully shifting its sales mix toward premium brands. This allows them to expand margins and offset lower overall consumption.

• Leading the Zero-Alcohol Shift: Their heavy early investment in Heineken 0.0 has given them a strong foothold in the exact segment where consumer growth is actually happening, acting as a natural hedge against declining alcohol sales.

• Pricing Power: As a global staple with significant brand equity, they have demonstrated a solid ability to pass on inflation costs to consumers without destroying their market share.

I tried to take an objective look at their current valuation and whether this defensive strategy is actually translating into long-term shareholder returns.

I’d love to hear your thoughts or critiques on the analysis!

open.substack.com

u/Electrical_County_61 — 4 days ago

▲ 6 r/ValueInvesting

Is the $830B Alcoholic Beverage Slump a Value Trap or a Buy?

The alcoholic beverage sector has seen over $830 billion in market value evaporate since 2021. Industry leaders like Diageo and Pernod Ricard are trading at decade lows, prompting a serious debate among fundamental investors: is this a generational entry point or a structural decline akin to big tobacco?

The headwinds are significant. Global volumes are shrinking as younger demographics pivot toward "mindful drinking," while persistent inflation erodes the premiumization trend that fueled the last decade of growth. Compounding this, new US import tariffs are threatening the margins of European exporters who heavily depend on the American market. While emerging markets in APAC and Africa offer some resilience, core Western markets are facing a grim combination of saturation and oversupply.

For value investors, the key is determining if the economic moats of these legacy brands remain intact or if we are witnessing permanent demand destruction. Does the current valuation provide a sufficient margin of safety, or is the industry simply a falling knife in a changing cultural landscape?

My full analysis is linked in this post.

open.substack.com

u/Electrical_County_61 — 9 days ago

▲ 9 r/ValueInvesting

Ericsson: The Hidden Backbone in Unstable Times

You can’t buy an Ericsson phone or open Ericsson apps, yet a massive part of our modern world runs on the equipment of this Swedish company. Ericsson forms the invisible spine of our global communication, building the mobile networks, antennas, and 5G systems we blindly rely on every single day. In an era where digital infrastructure is no longer just a technological luxury but a hard geopolitical asset, this company positions itself as an indispensable link. That is exactly what makes it an exceptionally attractive and stable investment in an otherwise highly volatile world.

The strength of the company lies in its absolute dominance and the incredibly high barriers to entry in the market it operates in. Designing and building telecom infrastructure requires billions in continuous technological research, navigating complex security certifications, and the ability to provide global support. It is practically impossible for new competitors to simply break into this space. Moreover, its largest global competitor, the Chinese
Huawei, is increasingly being locked out of Western countries due to strict regulations. What remains in the Western world is essentially a duopoly, where Ericsson consistently outperforms its biggest rival Nokia with better margins and by securing gigantic contracts in places like the United States.

What makes the business model so financially robust is the combination of hardware, software, and a colossal portfolio of tens of thousands of patents. Hardware opens the doors, but the real money is made afterward. Once a telecom provider installs the equipment, they are locked into the accompanying software updates, licenses, and maintenance contracts for years. The switching costs for these clients are simply too high, and the risk of network downtime is too great to just swap suppliers. This ensures a highly predictable, ironclad stream of revenue. Although the company has historically wasted capital when venturing outside its core activities to focus on the consumer market, its fundamental infrastructure engine continues to run flawlessly and profitably.

This defensive character, combined with deeply rooted long-term contracts and an essential technological position, offers a safe haven for anyone seeking stability during economic turbulence. For those who want to know exactly how this strategic advantage translates into accounting, all the specific figures, profit margins, and market shares are fully detailed in the publication.

Do any of you already own some Ericsson shares?

open.substack.com

u/Electrical_County_61 — 12 days ago

▲ 44 r/dknovonordisk+2 crossposts

Hey everyone, a while back I shared my deep dive on the battle between Eli Lilly and Novo Nordisk. In that post, I argued that while Lilly is currently viewed by the market as the offensive builder, we shouldn't count out Novo Nordisk, as they are patiently building their counterattack, especially in the oral drug market. Today, we got some major news for both companies that perfectly illustrates this dynamic. Novo reported their first quarter numbers for 2026 today and raised their 2026 outlook due to massive GLP-1 momentum. In my original post, I highlighted that oral drugs are the key to transforming the obesity space from an injection niche to a mass market. Novo is proving this thesis right now because their Wegovy pill, launched in the US in January 2026, just delivered the strongest-ever GLP-1 volume launch in US history, racking up over 1.3 million prescriptions in the first quarter alone. I previously noted that Lilly’s tirzepatide led in raw metabolic power and weight reduction. However, Novo just launched Wegovy HD, an injectable 7.2 mg dose, in the US, which has shown a mean weight loss of 20.7 percent, putting them right back in the heavyweight fight regarding efficacy. My deep dive also warned about the continuous drop in net prices due to rebates and pressure from pharmacy benefit managers. We saw this reflected in today's earnings because while reported first-quarter sales jumped 32 percent, heavily boosted by a 340B provision reversal, their adjusted sales actually decreased by 4 percent due to lower realized prices in the US.

Meanwhile, Eli Lilly saw its shares drop. The dip was triggered by a single reported case of liver failure associated with their weight-loss pill, Foundayo, which popped up in the FDA's adverse events database. Analysts from RBC and Evercore called the selloff an overreaction, pointing out that one unverified case does not make a signal and that the drug had a clean liver safety profile across 11,000 patients in Phase 3 trials. Why the sudden drop then? As I discussed in my valuation breakdown, Lilly is currently priced for absolute perfection, trading at a premium forward price-to-earnings ratio of around 45x as the ultimate compounder, while Novo trades at a much cheaper 12x to 13x. When a stock is priced for a winner-takes-all scenario, even a single adverse event report can temporarily spook the market. Overall, today's news reinforces the idea that we are heading toward a durable duopoly rather than a winner-takes-all market. Lilly continues to face the pressure of sky-high expectations, while Novo's focused, specialist approach with oral semaglutide is starting to pay off exactly as planned.

What do you guys think, has Novo proven that the market punished its valuation too harshly?

u/Electrical_County_61 — 17 days ago

▲ 121 r/EU_Economics+3 crossposts

I recently published a write-up about what I call "The Mother of Deals", specifically diving into the massive implications of the new EU-India trade agreement. I’m honestly surprised by how muted the market’s reaction has been so far. Usually, a structural shift of this magnitude causes significant ripples, but it feels like it is currently flying under the radar while everyone is distracted by US tech earnings and broader macroeconomic noise.

When you look at the underlying mechanics, this is a major net positive for European businesses. It creates a much stronger structural foundation and secures strategic supply chains that allow European industries to better compete on a global scale. While massive, export-heavy giants are always part of the equation, the real long-term value creation here actually goes much deeper, heavily benefiting sectors like machinery, pharma, and infrastructure. This isn't a short-term catalyst, but rather a sustainable value retention driver for the entire European corporate ecosystem.

Right now, the actual financial implications of this deal seem largely unpriced. It feels like one of those situations where the broader market will only wake up and react once the downstream effects actually start showing up in European earnings reports a few quarters from now.

I've attached the link to my full breakdown. Has anyone else been looking into the underlying mechanics of this deal? I am curious to hear your thoughts on why the market is sleeping on this deal.

u/Electrical_County_61 — 23 days ago

▲ 37 r/ValueInvesting

Everyone is looking at Nike’s massive drawdown and wondering if this is the time to buy the bottom. To be fair, the bullish case isn't crazy: it's an iconic global brand, they've shaken up leadership, and the stock is hovering around decade-low levels. A successful turnaround is absolutely on the table. However, investing is all about opportunity cost and risk-adjusted returns, and when you look at Nike objectively today, the math simply doesn't justify an entry right now.

Even after the brutal drop, Nike isn't trading at deep-value, "priced for disaster" levels. You are still paying a multiple that assumes management can fix the structural issues fairly quickly. If the turnaround takes longer than expected, which large-scale retail restructurings usually do, there is still plenty of room for the stock to fall further. Furthermore, Nike isn't just fighting its own supply chain and legacy inventory issues; they are actively losing the premium consumer to agile competitors like Hoka and On Running. Winning those buyers back will require heavy investment in innovation and marketing, which will likely keep margins depressed in the near term.

This brings us to the ultimate dealbreaker: opportunity cost. Why park your capital in a complex, multi-year "show-me" story with significant execution risk, when the broader market is full of companies offering better visibility, stronger momentum, and less uncertainty? Nike will probably figure it out and recover in the long run, but right now, you are taking on the risk of a messy restructuring without getting a wide enough margin of safety in return. Until there are concrete, measurable signs that top-line growth and market share are stabilizing, there are simply better, lower-risk places to put your money to work.

My reasoning is explained in detail in the article.

u/Electrical_County_61 — 25 days ago